Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 103. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply1655
Environment and infectious diseases1237
A step forward in the journey towards hookworm vaccines901
Listeria monocytogenes: a rare, deadly cause of peritonitis801
Surge of cutaneous leishmaniasis in Pakistan686
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply667
Research in brief596
Research in brief594
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting478
Role of the G20 in safe reopening of international travel465
Attention to skin-related neglected tropical diseases456
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect438
Infectious disease surveillance update372
Chronicling PEPFAR's work in Africa368
Ordinary people in extraordinary times360
Infectious disease surveillance update357
Rajendra Kapila314
Entering a labyrinth of COVID-19 stories277
Promoting diversity and equity in publishing277
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7275
SARS-CoV-2 incidence and vaccine escape267
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges266
Adaora “Ada” Alise Adimora263
The next chapter for Africa's genomic initiatives255
The superiority of bivalent over monovalent booster vaccines253
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum248
DNDi receives Dutch funding boost244
COVID-19 vaccination protects children and adolescents240
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study234
Can the USA return to pre-COVID-19 normal by July 4?234
Reflecting on lessons from the 2014–16 Ebola virus outbreak218
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis218
Bold measures to accelerate malaria elimination216
A patient with secondary syphilis following incomplete treatment of primary infection210
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations210
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial205
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study205
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review203
HIV vaccine trial failure201
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden193
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial190
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial187
Threat of HIV and tuberculosis drug resistance after US funding cuts179
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study177
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria169
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines163
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic162
Updated criteria for paediatric sepsis and septic shock162
Transitioning to endemicity with COVID-19 research162
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations161
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial157
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation156
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1155
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C155
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis155
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial154
Mpox in people with past infection or a complete vaccination course: a global case series153
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study152
The interplay between COVID-19 restrictions and vaccination151
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study150
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin147
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco145
The importance of understanding the infectious microenvironment142
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2140
Post-viral sequelae of COVID-19 and influenza140
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention139
Supporting healthcare access for refugees and migrants138
Assessment of experimental malaria vaccine induced protection in pre-exposed populations137
History and evolution of tuberculosis and global health137
Election of Regional Director for the Western Pacific136
High-dose primaquine reduces vivax relapses: time for change134
The implications of mpox breakthrough infections on future vaccination strategies134
Severe influenza: is there a role for antiviral combinations?130
Sizing the reservoirs of malaria transmission: the contribution of school-aged children130
Correction to Lancet Infect Dis 2021; 21: 962–74129
Emil Gotschlich128
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world127
Interplay of infection and vaccination in long-term protection from COVID-19127
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa127
Global cholera resurgence—a preventable tragedy126
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study126
The global burden of cryptococcosis—a neglected tropical disease?126
Immune evasiveness of SARS-CoV-2 variants and vaccine selection126
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis126
Worrying lack of funding for tuberculosis123
Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study123
Elisabeth Presterl—always looking forward122
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis121
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site119
Super-spreaders: a historical review118
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant118
Addressing the shortage of cholera vaccines116
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update115
Malaria vaccine development in Mali: a step towards transmission-blocking strategies114
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms113
Correction to Lancet Infect Dis 2023; 23: e469112
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5111
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0110
Research in brief109
Correction to Lancet Infect Dis 2021; 21: 629–36109
Full-dose NSAIDs at the first sign of respiratory infection?106
The response of mpox-associated inflammatory syndrome to steroid therapy105
Theresa Ochoa—staying on top of infectious diseases in Peru104
0.14455103874207